ALLISON SABIN: Open Payments
NPI 1811582836 · TOOELE, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,507 in 83 payments from 16 companies in 2025. Trend: 2023 $1,514 · 2024 $1,659 · 2025 $1,507
Food & beverage: $1,507
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $381 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $243 |
| Janssen Biotech, Inc. | 13 | $209 |
| Aimmune Therapeutics, Inc. | 7 | $151 |
| Ardelyx, Inc. | 8 | $147 |
| GENZYME CORPORATION | 4 | $74 |
| Madrigal Pharmaceuticals | 3 | $72 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Celltrion USA Inc. | 2 | $40 |
| Novo Nordisk Inc | 2 | $31 |
Products named: RINVOQ, ENTYVIO, TREMFYA, IBSRELA, DUPIXENT, VOWST, REZDIFFRA, ZENPEP.
Industry payments across UT — which companies pay providers there.
